Patients with metastatic colorectal cancer (mCRC) treated with the combination of the investigational polo-like kinase 1 inhibitor, onvansertib, plus FOLFIRI (Irinotecan, Fluorouracil [5-FU], and folinic acid [leucovorin]), and bevacizumab (Avastin) had a 100% clinical benefit rate at 8 weeks by radiographic response in a phase Ib study presented at the 2020 Gastrointestinal Cancers Symposium. Data […]

Innovative treatments have turned the tables somewhat in the battle against cancer but one stumbling block appears to be pricing. CAR-T cell therapy can cost more than $1.5 million including the $475,000 cost of the drug (in this case, Kymriah from Novartis). “We are seeing that price is becoming a barrier because if you can imagine, hundreds of thousands of […]

The announcement during last week’s J.P. Morgan Healthcare Conference of a deal between Novartis and England’s National Health Service to supply a cholesterol-lowering drug dosed only twice per year marked a significant event in the history of a class of drugs that only entered the market two years ago, but whose development goes back decades. Biotech Showcase […]